CRBP
Price
$4.00Alerts
Change
+$0.07 (+1.78%)
Updated
Nov 11 closing price
Capitalization
59.38M
Earnings call today
Intraday BUY SELL Signals
NRXS
Price
$6.08Alerts
Change
-$0.18 (-2.88%)
Updated
Nov 11, 04:59 PM (EDT)
Capitalization
78.36M
Intraday BUY SELL Signals
Interact to see
Advertisement

CRBP vs NRXS

CRBP vs NRXS Comparison Chart in %
loading
loading
View a ticker or compare two or three
VS
CRBP vs. NRXS commentary
Nov 12, 2026

To compare these two companies we present long-term analysis, their fundamental ratings and make comparative short-term technical analysis which are presented below. The conclusion is CRBP is a Hold and NRXS is a Hold.

Interact to see
Advertisement
SUMMARIES
A.I.Advisor
a Summary for CRBP with price predictions
Nov 10, 2026

CRBP's MACD Histogram just turned positive

The Moving Average Convergence Divergence (MACD) for CRBP turned positive on October 22, 2026. Looking at past instances where CRBP's MACD turned positive, the stock continued to rise in 40 of 44 cases over the following month. The odds of a continued upward trend are 90%.

Price Prediction Chart

Technical Analysis (Indicators)

Bullish Trend Analysis

The RSI Indicator points to a transition from a downward trend to an upward trend -- in cases where CRBP's RSI Indicator exited the oversold zone, 31 of 48 resulted in an increase in price. Tickeron's analysis proposes that the odds of a continued upward trend are 65%.

The Stochastic Oscillator suggests the stock price trend may be in a reversal from a downward trend to an upward trend. 45 of 61 cases where CRBP's Stochastic Oscillator exited the oversold zone resulted in an increase in price. Tickeron's analysis proposes that the odds of a continued upward trend are 74%.

Following a +28.01% 3-day Advance, the price is estimated to grow further. Considering data from situations where CRBP advanced for three days, in 227 of 280 cases, the price rose further within the following month. The odds of a continued upward trend are 81%.

CRBP may jump back above the lower band and head toward the middle band. Traders may consider buying the stock or exploring call options.

Bearish Trend Analysis

The 50-day moving average for CRBP moved below the 200-day moving average on October 07, 2026. This could be a long-term bearish signal for the stock as the stock shifts to an downward trend.

Following a 3-day decline, the stock is projected to fall further. Considering past instances where CRBP declined for three days, the price rose further in 50 of 62 cases within the following month. The odds of a continued downward trend are 87%.

The Aroon Indicator for CRBP entered a downward trend on November 10, 2026. This could indicate a strong downward move is ahead for the stock. Traders may want to consider selling the stock or buying put options.

Fundamental Analysis (Ratings)

The Tickeron PE Growth Rating for this company is 8 (best 1 - 100 worst), pointing to outstanding earnings growth. The PE Growth rating is based on a comparative analysis of stock PE ratio increase over the last 12 months compared against S&P 500 index constituents.

The Tickeron Valuation Rating of 64 (best 1 - 100 worst) indicates that the company is fair valued in the industry. This rating compares market capitalization estimated by our proprietary formula with the current market capitalization. This rating is based on the following metrics, as compared to industry averages: P/B Ratio (0.581) is normal, around the industry mean (3.498). P/E Ratio (-0.502) is within average values for comparable stocks, (-1.193). Projected Growth (PEG Ratio) (0.000) is also within normal values, averaging (9.059). Dividend Yield (0.000) settles around the average of (130.981) among similar stocks. P/S Ratio (0.000) is also within normal values, averaging (440.869).

The Tickeron Price Growth Rating for this company is 93 (best 1 - 100 worst), indicating slightly worse than average price growth. CRBP’s price grows at a lower rate over the last 12 months as compared to S&P 500 index constituents.

The Tickeron SMR rating for this company is 98 (best 1 - 100 worst), indicating weak sales and an unprofitable business model. SMR (Sales, Margin, Return on Equity) rating is based on comparative analysis of weighted Sales, Income Margin and Return on Equity values compared against S&P 500 index constituents. The weighted SMR value is a proprietary formula developed by Tickeron and represents an overall profitability measure for a stock.

The Tickeron Profit vs. Risk Rating rating for this company is 100 (best 1 - 100 worst), indicating that the returns do not compensate for the risks. CRBP’s unstable profits reported over time resulted in significant Drawdowns within these last five years. A stable profit reduces stock drawdown and volatility. The average Profit vs. Risk Rating rating for the industry is 93, placing this stock worse than average.

A.I.Advisor
a Summary for NRXS with price predictions
Nov 10, 2026

NRXS in upward trend: price may jump up because it broke its lower Bollinger Band on November 05, 2026

NRXS may jump back above the lower band and head toward the middle band. Traders may consider buying the stock or exploring call options. In 24 of 27 cases where NRXS's price broke its lower Bollinger Band, its price rose further in the following month. The odds of a continued upward trend are 89%.

Price Prediction Chart

Technical Analysis (Indicators)

Bullish Trend Analysis

The Stochastic Oscillator suggests the stock price trend may be in a reversal from a downward trend to an upward trend. 29 of 35 cases where NRXS's Stochastic Oscillator exited the oversold zone resulted in an increase in price. Tickeron's analysis proposes that the odds of a continued upward trend are 83%.

Following a +8.18% 3-day Advance, the price is estimated to grow further. Considering data from situations where NRXS advanced for three days, in 123 of 147 cases, the price rose further within the following month. The odds of a continued upward trend are 84%.

Bearish Trend Analysis

The Momentum Indicator moved below the 0 level on October 29, 2026. You may want to consider selling the stock, shorting the stock, or exploring put options on NRXS as a result. In 61 of 68 cases where the Momentum Indicator fell below 0, the stock fell further within the subsequent month. The odds of a continued downward trend are 90%.

The Moving Average Convergence Divergence Histogram (MACD) for NRXS turned negative on October 27, 2026. This could be a sign that the stock is set to turn lower in the coming weeks. Traders may want to sell the stock or buy put options. Tickeron's A.I.dvisor looked at 30 similar instances when the indicator turned negative. In 27 of the 30 cases the stock turned lower in the days that followed. This puts the odds of success at 90%.

NRXS moved below its 50-day moving average on November 02, 2026 date and that indicates a change from an upward trend to a downward trend.

The 10-day moving average for NRXS crossed bearishly below the 50-day moving average on November 09, 2026. This indicates that the trend has shifted lower and could be considered a sell signal. In 12 of 12 past instances when the 10-day crossed below the 50-day, the stock continued to move higher over the following month. The odds of a continued downward trend are 90%.

Following a 3-day decline, the stock is projected to fall further. Considering past instances where NRXS declined for three days, the price rose further in 50 of 62 cases within the following month. The odds of a continued downward trend are 90%.

Fundamental Analysis (Ratings)

The Tickeron PE Growth Rating for this company is 32 (best 1 - 100 worst), pointing to outstanding earnings growth. The PE Growth rating is based on a comparative analysis of stock PE ratio increase over the last 12 months compared against S&P 500 index constituents.

The Tickeron Price Growth Rating for this company is 40 (best 1 - 100 worst), indicating steady price growth. NRXS’s price grows at a higher rate over the last 12 months as compared to S&P 500 index constituents.

The Tickeron Valuation Rating of 74 (best 1 - 100 worst) indicates that the company is slightly overvalued in the industry. This rating compares market capitalization estimated by our proprietary formula with the current market capitalization. This rating is based on the following metrics, as compared to industry averages: P/B Ratio (11.641) is normal, around the industry mean (3.498). P/E Ratio (-8.211) is within average values for comparable stocks, (-1.193). Projected Growth (PEG Ratio) (0.000) is also within normal values, averaging (9.059). Dividend Yield (0.000) settles around the average of (130.981) among similar stocks. P/S Ratio (14.225) is also within normal values, averaging (440.869).

The Tickeron SMR rating for this company is 99 (best 1 - 100 worst), indicating weak sales and an unprofitable business model. SMR (Sales, Margin, Return on Equity) rating is based on comparative analysis of weighted Sales, Income Margin and Return on Equity values compared against S&P 500 index constituents. The weighted SMR value is a proprietary formula developed by Tickeron and represents an overall profitability measure for a stock.

The Tickeron Profit vs. Risk Rating rating for this company is 100 (best 1 - 100 worst), indicating that the returns do not compensate for the risks. NRXS’s unstable profits reported over time resulted in significant Drawdowns within these last five years. A stable profit reduces stock drawdown and volatility. The average Profit vs. Risk Rating rating for the industry is 93, placing this stock worse than average.

FUNDAMENTALS RATINGS
CRBP: Fundamental Ratings
CRBP
OUTLOOK RATING
1..100
5
VALUATION
overvalued / fair valued / undervalued
1..100
64
Fair valued
PROFIT vs RISK RATING
1..100
100
SMR RATING
1..100
98
PRICE GROWTH RATING
1..100
93
P/E GROWTH RATING
1..100
8
SEASONALITY SCORE
1..100
50

Tickeron ratings are formulated such that a rating of 1 designates the most successful stocks in a given industry, while a rating of 100 points to the least successful stocks for that industry.

TECHNICAL ANALYSIS
Technical Analysis
CRBPNRXS
RSI
ODDS (%)
Bullish Trend 2 days ago
65%
N/A
Stochastic
ODDS (%)
Bullish Trend 2 days ago
74%
Bullish Trend 2 days ago
83%
Momentum
ODDS (%)
N/A
Bearish Trend 2 days ago
90%
MACD
ODDS (%)
Bullish Trend 2 days ago
90%
Bearish Trend 2 days ago
90%
TrendWeek
ODDS (%)
Bullish Trend 2 days ago
82%
Bearish Trend 2 days ago
89%
TrendMonth
ODDS (%)
Bearish Trend 2 days ago
88%
Bearish Trend 2 days ago
89%
Advances
ODDS (%)
Bullish Trend 2 days ago
81%
Bullish Trend 3 days ago
84%
Declines
ODDS (%)
Bearish Trend 7 days ago
87%
Bearish Trend 9 days ago
90%
BollingerBands
ODDS (%)
Bullish Trend 2 days ago
82%
Bullish Trend 2 days ago
89%
Aroon
ODDS (%)
Bearish Trend 2 days ago
90%
N/A
COMPARISON
Comparison
Nov 12, 2026
Stock price -- (CRBP: $3.93 vs. NRXS: $6.25)
Brand notoriety: CRBP and NRXS are both not notable
Both companies represent the Biotechnology industry
Current volume relative to the 65-day Moving Average: CRBP: 55% vs. NRXS: 50%
Market capitalization -- CRBP: $59.38M vs. NRXS: $78.36M
CRBP [@Biotechnology] is valued at $59.38M. NRXS’s [@Biotechnology] market capitalization is $78.36M. The market cap for tickers in the [@Biotechnology] industry ranges from $58 to $138.67B. The average market capitalization across the [@Biotechnology] industry is $2.23B.

Long-Term Analysis

It is best to consider a long-term outlook for a ticker by using Fundamental Analysis (FA) ratings. The rating of 1 to 100, where 1 is best and 100 is worst, is divided into thirds. The first third (a green rating of 1-33) indicates that the ticker is undervalued; the second third (a grey number between 34 and 66) means that the ticker is valued fairly; and the last third (red number of 67 to 100) reflects that the ticker is overvalued. We use an FA Score to show how many ratings show the ticker to be undervalued (green) or overvalued (red).

CRBP’s FA Score shows that 1 FA rating(s) are green while NRXS’s FA Score has 1 green FA rating(s).

  • CRBP’s FA Score: 1 green, 4 red.
  • NRXS’s FA Score: 1 green, 4 red.
According to our system of comparison, NRXS is a better buy in the long-term than CRBP.

Short-Term Analysis

It is best to consider a short-term outlook for a ticker by using Technical Analysis (TA) indicators. We use Odds of Success as the percentage of outcomes which confirm successful trade signals in the past.

If the Odds of Success (the likelihood of the continuation of a trend) for each indicator are greater than 50%, then the generated signal is confirmed. A green percentage from 90% to 51% indicates that the ticker is in a bullish trend. A red percentage from 90% - 51% indicates that the ticker is in a bearish trend. All grey percentages are below 50% and are considered not to confirm the trend signal.

CRBP’s TA Score shows that 5 TA indicator(s) are bullish while NRXS’s TA Score has 3 bullish TA indicator(s).

  • CRBP’s TA Score: 5 bullish, 3 bearish.
  • NRXS’s TA Score: 3 bullish, 5 bearish.
According to our system of comparison, CRBP is a better buy in the short-term than NRXS.

Price Growth

CRBP (@Biotechnology) experienced а +1.55% price change this week, while NRXS (@Biotechnology) price change was -5.02% for the same time period.

The average weekly price growth across all stocks in the @Biotechnology industry was +4.90%. For the same industry, the average monthly price growth was -2.72%, and the average quarterly price growth was -13.41%.

Reported Earning Dates

CRBP is expected to report earnings on Nov 11, 2026.

Industries' Descriptions

@Biotechnology (+4.90% weekly)

Biotechnology involves genetic or protein engineering to produce medicines/therapies for treating and preventing ailments. The industry also provides crucial ingredients for diagnostics. This multi-billion-dollar industry is heavily focused on research and development, as companies attempt to continually come up with cutting-edge solutions for health. New discoveries for the treatment of diseases provide opportunities for growth for a company in this industry. Discoveries, however, must pass the regulatory approval from the U.S. Food and Drug Administration (FDA) before they can make it to markets. Amgen Inc., Gilead Sciences, Inc. and Celgene Corporation are examples of companies in this industry.

View a ticker or compare two or three
Interact to see
Advertisement

NRXS and

Correlation & Price change

A.I.dvisor indicates that over the last year, NRXS has been loosely correlated with CVM. These tickers have moved in lockstep 58% of the time. This A.I.-generated data suggests there is some statistical probability that if NRXS jumps, then CVM could also see price increases.

1D
1W
1M
1Q
6M
1Y
5Y
Ticker /
NAME
Correlation
To NRXS
1D Price
Change %
NRXS100%
-5.45%
CVM - NRXS
58%
Loosely correlated
+4.44%
TWST - NRXS
28%
Poorly correlated
-2.37%
CRBP - NRXS
27%
Poorly correlated
+11.65%
PVLA - NRXS
27%
Poorly correlated
-3.08%
NTLA - NRXS
27%
Poorly correlated
-7.76%
More
Interesting Tickers
1D
1W
1M
1Q
6M
1Y
5Y
1 Day
ETFs / NAMEPrice $Chg $Chg %
LRCU22.490.21
+0.94%
Tradr 2X Long LRCX Daily ETF (LRCU)
FYEE29.37N/A
N/A
Fidelity Yield Enhanced Equity ETF (FYEE)
GXPC27.26-0.03
-0.11%
Global X PureCap MSCI Communication Services ETF (GXPC)
KLMT34.10-0.18
-0.53%
Invesco MSCI Global Climate 500 ETF (KLMT)
EUVX8.22-0.15
-1.75%
Corgi Lithography & Semiconductor Photonics 2x Daily ETF (EUVX)